LivaNova (LIVN) Q1 2026 Earnings Transcript

LivaNova reported Q1 revenue of $362 million, up 11% constant currency, with cardiopulmonary revenue rising 14% to $209 million and epilepsy revenue increasing 8%. Management raised 2026 revenue growth guidance to 7%-8% from 6%-7%, lifted cardiopulmonary growth guidance to 8.5%-9.5%, and increased epilepsy guidance to 6%-7%, while also guiding adjusted EPS to $4.20-$4.30. The quarter also brought a major OSA milestone with FDA approval of aura6000 and strong 12-month OSPREY data, though free cash flow fell to $4 million and guidance still reflects supply-chain and Middle East-related cost headwinds.

Analysis

LivaNova is transitioning from a “proof of execution” story to a “capacity conversion” story. The key second-order effect is that revenue upside is increasingly constrained by manufacturing and component availability rather than demand, which usually compresses the path to margin expansion but also makes missed numbers less likely if supply keeps improving. That dynamic is more durable than a one-quarter beat: once customers requalify into the installed base and surgeons build comfort with the upgrade cycle, utilization tends to become sticky and raises switching costs for competitors.

The more interesting catalyst is not the headline OSA approval; it is that OSA gives the market a new, separable growth leg with a multi-year staging path, while core businesses keep funding it. In the near term, the market may underappreciate that reimbursement improvement in epilepsy can create a self-reinforcing loop: better economics expand the addressable center base, which increases procedure frequency, which then improves data dissemination and peer adoption. If that loop holds, earnings revisions should continue even if top-line growth normalizes modestly.

The main risk is that investors extrapolate current optimism too far into the OSA rollout. This is still a 2027-2028 monetization story, so any slippage in FDA/commercial sequencing, coding decisions, or clinical-to-reimbursement translation could create a valuation air pocket after the initial approval-driven enthusiasm fades. Another underappreciated risk is free cash flow: capex is rising faster than earnings, so if working capital stays elevated, the market could de-rate the stock despite attractive reported growth.

Key Decisions for Investors

• Long LIVN on any 3%-5% pullback over the next 2-4 weeks; thesis is that 2026 guidance revisions still have room to move up as supply improves and epilepsy reimbursement broadens, with limited downside unless OSA execution slips.
• Consider a LIVN / BSX pair trade over 3-6 months: long LIVN for underappreciated operating leverage and reimbursement-driven mix improvement, short a larger-cap medtech with slower revision momentum to isolate idiosyncratic upside.
• Buy LIVN Jan-2027 call spreads if implied volatility stays below the post-earnings range; risk/reward favors optionality on OSA commercialization without paying for full 2027 launch certainty.
• Fade the quarter-to-quarter FCF narrative on a 6-12 month horizon only if capex remains elevated but growth decelerates; otherwise treat weak FCF as a temporary reinvestment phase, not a thesis break.
• If the stock rallies >10% on OSA headlines, trim into strength: the market is likely to front-load value for a 2027 revenue stream, leaving a better entry once launch timing and reimbursement path are scrutinized.